Cancer

CancerVAX CEO Ryan Davies Discusses the Company’s Growing Pipeline of Cancer Treatments

The Company’s development pipeline now includes three projects with UCLALEHI, Utah, Sept. 14, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a…

1 year ago

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic…

1 year ago

Sequana Medical announces H1 2023 results and provides business update

PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international…

1 year ago

Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to…

1 year ago

Champions Oncology Reports Quarterly Revenue of $12.6 Million

HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is…

1 year ago

Sarah Bush Lincoln Adopts DoseMe Precision Dosing Platform to Improve Overall Level of Patient Care

Hospital transitions to AUC-based dosing to achieve a comprehensive view of patient course of therapy, renal function, and overall population…

1 year ago

Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemerJaguar is…

1 year ago

Cosmos Health Starts Stock Buyback Program

CHICAGO, IL / ACCESSWIRE / September 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers…

1 year ago

HOOKIPA Announces Executive Leadership Change

NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a…

1 year ago